Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Sandip Kaledhonkar | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Sandip Kaledhonkar | Drug Discovery and Development | Research Excellence Award

Indian Institute of Technology Bombay | India

Assoc. Prof. Dr. Sandip Kaledhonkar is a distinguished scientist whose work spans biophysics, structural biology, cryo-electron microscopy, and molecular microbiology. He currently serves in the Department of Biosciences and Bioengineering at the Indian Institute of Technology Bombay, where he contributes to cutting-edge research, innovative teaching, and academic mentorship. Prior to his current role, he progressed through key academic and research appointments, including his tenure as Assistant Professor at IIT Bombay, a scientific role at the Haffkine Institute for Training, Research and Testing in Mumbai, and an impactful post-doctoral fellowship at Columbia University Medical Center in New York. These experiences collectively shaped his expertise in structural dynamics, cryo-EM methodologies, and molecular interactions critical to understanding biological systems.Dr. Kaledhonkar earned his Ph.D. in Physics from Oklahoma State University, where he conducted foundational work on the Structural Dynamics of Photoactive Yellow Protein under the guidance of Dr. Aihua Xie. He further strengthened his academic foundation with an M.Sc. and B.Sc. in Physics from the University of Pune. His teaching portfolio reflects his multidisciplinary strengths, covering subjects such as Mathematics for Biologists, Experimental Techniques in Biomedical Engineering, Computational Biology, cryo-Electron Microscopy, and core undergraduate biology.His research contributions have significantly advanced the field, with notable publications including titles such as In Silico Identification of Potential Inhibitors of Mycobacterium tuberculosis DNA Gyrase from Phytoconstituents of Indian Medicinal Plants, Cryo-EM Reconstruction of the phiK601 Jumbo Phage Head, VCP/p97, a Host AAA-ATPase Exhibits Bacteriolytic Activity for Clearance of Microbial Infection, Conformational Flexibility Associated with Remote Residues Regulate the Kinetic Properties of Glutamate Dehydrogenase, and Application of Bio-Layer Interferometry for the Analysis of Ribosome-Protein Interactions. Other influential works include Physiochemical Characterization of a Potential Klebsiella Phage MKP-1, Not All Photoactive Yellow Proteins Are Built Alike, and landmark cryo-EM studies such as Late Steps in Bacterial Translation Initiation Visualized Using Time-Resolved Cryo-EM and Key Intermediates in Ribosome Recycling Visualized by Time-Resolved Cryo-Electron Microscopy. His scholarly record also features important methodological contributions, including Single Particle Cryo-Electron Microscopy and A Fast and Effective Microfluidic Spraying-Plunging Method for High-Resolution Single-Particle Cryo-EM.Dr. Kaledhonkar’s excellence has been recognized through numerous honors, including prestigious microscopy, teaching, and research awards, as well as membership in India’s premier scientific academies. His work continues to influence modern bioscience research, inspiring new advancements in structural biology and biomedical innovation.

Profile: Google Scholar

Featured Publications

Feng, X., Fu, Z., Kaledhonkar, S., Jia, Y., Shah, B., Jin, A., Liu, Z., Sun, M., & Chen, B. (2017). A fast and effective microfluidic spraying‑plunging method for high‑resolution single‑particle cryo‑EM. Structure, 25(4), 663‑670.e3.

Chen, B., Kaledhonkar, S., Sun, M., Shen, B., Lu, Z., Barnard, D., & Lu, T. M. (2015). Structural dynamics of ribosome subunit association studied by mixing‑spraying time‑resolved cryogenic electron microscopy. Structure, 23(6), 1097‑1105.

Fu, Z., Indrisiunaite, G., Kaledhonkar, S., Shah, B., Sun, M., & Chen, B. (2019). The structural basis for release factor activation during translation termination revealed by time‑resolved cryogenic electron microscopy. Biophysical Journal, 116(3), 574a‑575a.

Fu, Z., Kaledhonkar, S., Borg, A., Sun, M., Chen, B., Grassucci, R. A., & Ehrenberg, M. (2016). Key intermediates in ribosome recycling visualized by time‑resolved cryoelectron microscopy. Structure, 24(12), 2092‑2101.

Horst, M. A., Stalcup, T. P., Kaledhonkar, S., Kumauchi, M., Hara, M., & Xie, A. (2009). Locked chromophore analogs reveal that photoactive yellow protein regulates biofilm formation in the deep‑sea bacterium Idiomarina loihiensis. Journal of the American Chemical Society, 131(47), 17443‑17451.

Kaledhonkar, S., Fu, Z., White, H., & Frank, J. (2018). Time‑resolved cryo‑electron microscopy using a microfluidic chip. In Protein Complex Assembly: Methods and Protocols (pp. 59‑71).

Kaledhonkar, S., Hara, M., Stalcup, T. P., Xie, A., & Hoff, W. D. (2013). Strong ionic hydrogen bonding causes a spectral isotope effect in photoactive yellow protein. Biophysical Journal, 105(11), 2577‑2585.

Palaniyandi Velusamy | Drug Discovery and Development |

Published on by Top Pharmaceutical

Prof. Dr. Palaniyandi Velusamy | Drug Discovery and Development | Research Excellence Award

Sree Balaji Medical College and Hospital  | India

Prof. Dr. Palaniyandi Velusamy is a distinguished researcher, academic leader, and biotechnology expert recognized for his extensive contributions to microbiology, nanobiotechnology, biosciences, and antibacterial drug research. He began his academic journey with foundational studies in botany and biochemistry before completing his doctoral research at the University of Madras, where he specialized in antibacterial agents and developed research competencies that shaped his future scientific pursuits. Following his Ph.D., he undertook multiple prestigious post-doctoral fellowships across internationally reputed institutions in Taiwan and South Korea, including Academia Sinica, Korea University, and Chonnam National University, where he contributed to advanced research in nanotechnology, microbial applications, and bioengineering. He later served as a Visiting Professor at Kyung Hee University in South Korea, strengthening his global academic footprint. In India, he built a progressive academic career at SRM University, where he contributed as Assistant Professor, Associate Professor, and later took on key departmental responsibilities including Deputy Controller of Examinations, Research Coordinator, Department Treasurer, Class In-Charge for B.Tech and M.Tech programs, Counsellor, and Course Coordinator for key subjects such as Microbial Technology, Microbiology, Enzyme Technology, Bionanotechnology, Green Chemistry, Pharmaceutical Engineering, and Phytochemistry. His academic leadership expanded further when he joined Sree Balaji Medical College and Hospital, Chennai, where he served as Professor and currently holds the role of Joint Director at the Innovation & Incubation Centre, guiding institutional innovation, research development, and technology incubation.Prof. Velusamy’s contributions to scientific publishing are extensive; he serves as Editor for Scientific Reports (Nature Publishing Group), Associate Editor for Frontiers in Bioengineering and Biotechnology, Editor for the Global Journal of Pathology and Microbiology, Guest Editor for Biosensors, and Editorial Board Member for the Austin Journal of Nanomedicine & Nanotechnology. He is also an invited reviewer for globally recognized journals including Colloids and Surfaces B, Spectrochimica Acta Part A, Heliyon, and the International Journal of Biological Macromolecules.

Profile: Orcid

Featured Publications

Krishnan, N., Singh, P. K., Sakthivelu, M., Velusamy, P., Gopinath, S. C. B., & Raman, P. (2024). Influence of thermal treatment on extraction and characteristics of phytochemicals from rhizome of _Acorus calamus L_. Biomass Conversion and Biorefinery. doi:10.1007/s13399-022-03415-y

Velusamy, P., Jeyanthi, V., Pachaiappan, R., Anbu, P., & Gopinath, S. C. B. (2024). Secretion of 2,4‑di‑tert‑butylphenol by a new _Pseudomonas strain SBMCH11: A tert‑butyl substituted phenolic compound displayed antibacterial efficacy_. Results in Chemistry, 6, 101593. doi:10.1016/j.rechem.2024.101593

Velusamy, P., Su, C.-H., Ramasamy, P., Arun, V., Rajnish, N., Raman, P., Baskaralingam, V., Kumar, S. M. S., & Gopinath, S. C. B. (2023). Volatile Organic Compounds as Potential Biomarkers for Noninvasive Disease Detection by Nanosensors: A Comprehensive Review. Critical Reviews in Analytical Chemistry, 53(4), 1‑30. doi:10.1080/10408347.2022.2043145

Soundararajan, P., Parthasarathy, S., Sakthivelu, M., Karuppiah, K. M., Velusamy, P., Gopinath, S. C. B., & Raman, P. (2023). Effects of Consuming Repeatedly Heated Edible Oils on Cardiovascular Diseases: A Narrative Review. Current Medicinal Chemistry, 30(30), 1‑18. doi:10.2174/0109298673250752230921090452

Ramesh, V., Kulkarni, S. A., Velusamy, P., Devadasan, V., Devaraju, P., Rajnish, K. N., Madhavan, T., Anbu, P., Ramasamy, P., & Sundarraj, R. (2022). Current Update of Phytotherapeutic Agents in the Treatment of COVID‑19: <i>In‑Silico</i> Based Virtual Screening Approach for the Development of Antiviral Drug. Frontiers in Bioscience‑Landmark, 27(4), 123. doi:10.31083/J.FBL2704123

Parthasarathy, S., Soundararajan, P., Krishnan, N., Karuppiah, K. M., Devadasan, V., Prabhu, D., Rajamanikandan, S., Velusamy, P., Gopinath, S. C. B., & Raman, P. (2022). Detection of adulterants from common edible oils by GC‑MS. Biomass Conversion and Biorefinery, 12(5), 1‑12. doi:10.1007/S13399-022-02913-3

Zaneta Nikolovska-Coleska | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Zaneta Nikolovska-Coleska | Drug Discovery and Development | Best Researcher Award

University of Michigan Medical School Department of Pathology | United States

Prof. Dr. Zaneta Nikolovska-Coleska is an accomplished pharmaceutical chemist and molecular pharmacologist recognized for her groundbreaking work in the design, synthesis, and development of molecularly targeted small molecules for cancer treatment. She earned her foundational and advanced degrees in pharmaceutical chemistry from the Faculty of Pharmacy at the University Ss. Cyril and Methodius in Skopje, where she also began her academic career as a young assistant and later advanced through multiple teaching and research positions. Her dedication to chemical sciences and biomedical innovation led her to the University of Michigan, Ann Arbor, where she currently serves as a Professor in the Department of Pathology and Associate Dean for Graduate and Postdoctoral Studies.Dr. Nikolovska-Coleska’s research is centered on the discovery of small molecule inhibitors that target protein–protein interactions involved in apoptosis, oncogenic signaling pathways, and epigenetic regulation. Her laboratory investigates mechanisms such as Mcl-1–Bim/Noxa, Bfl-1–Bim/Noxa, EZH2–p38 MAP kinase interactions, and histone methyltransferase activities, contributing to the identification of novel therapeutic targets for various malignancies. Through her integrative approach, combining chemical biology, medicinal chemistry, and translational oncology, she has developed promising compounds for the modulation of signaling pathways implicated in cancer progression and resistance.Her clinical and translational research extends into precision medicine, where she applies functional assays to predict anti-cancer drug responses, aiming to enhance individualized therapeutic strategies. As a clinician-research scholar and educator, she has mentored numerous postdoctoral fellows, clinical trainees, and graduate students, guiding them in developing innovative research methodologies and critical scientific reasoning.Throughout her illustrious career, Dr. Nikolovska-Coleska has played pivotal roles in multiple large-scale research initiatives, serving as Principal Investigator, Co-Investigator, and Mentor on numerous national and international grants focused on cancer biology, aging, and drug discovery. Her collaborations with global scientific institutions and pharmaceutical organizations have contributed to the advancement of targeted therapies, including the development of inhibitors against oncogenic proteins such as DOT1L, Mcl-1, EZH2, and PAPP-A.In addition to her research excellence, Dr. Nikolovska-Coleska has made outstanding contributions to academic leadership. As Director of the Molecular and Cellular Pathology Graduate Program and Associate Director of Academic Programs in Biomedical Sciences, she has overseen curriculum development, student recruitment, academic policy, and interdisciplinary research training. Her vision continues to shape the next generation of biomedical scientists, emphasizing the integration of molecular insights with clinical applications.Through her scholarly achievements, mentorship, and leadership, Prof. Dr. Zaneta Nikolovska-Coleska stands as a leading figure in pharmaceutical chemistry and translational oncology, dedicated to advancing science that bridges molecular discovery with therapeutic innovation.

Profile: Google Scholar

Featured Publications

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., et al. (2006). Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2−p53 interaction. Journal of Medicinal Chemistry, 49(12), 3432–3435.

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences, 105(10), 3933–3938.

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., et al. (2005). Structure-based design of potent non-peptide MDM2 inhibitors. Journal of the American Chemical Society, 127(29), 10130–10131.

Nikolovska-Coleska, Z., Wang, R., Fang, X., Pan, H., Tomita, Y., Li, P., Roller, P. P., et al. (2004). Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Analytical Biochemistry, 332(2), 261–273.

Nikolovska-Coleska, Z., Xu, L., Hu, Z., Tomita, Y., Li, P., Roller, P. P., Wang, R., et al. (2004). Discovery of embelin as a cell-permeable, small-molecular-weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine. Journal of Medicinal Chemistry, 47(10), 2430–2440.

Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., et al. (2021). Machine learning approaches and databases for prediction of drug–target interaction: A survey paper. Briefings in Bioinformatics, 22(1), 247–269.

Wang, G., Nikolovska-Coleska, Z., Yang, C. Y., Wang, R., Tang, G., Guo, J., et al. (2006). Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. Journal of Medicinal Chemistry, 49(21), 6139–6142.

Xiangxuan Zhao | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Xiangxuan Zhao | Drug Discovery and Development | Best Researcher Award

Liaoning University of Traditional Chinese Medicine | China

Prof. Xiangxuan Zhao is a distinguished cell biologist and an eminent academic leader renowned for his pioneering contributions to the field of natural medicine-derived anti-cancer therapeutics. Serving as Professor, Doctoral Supervisor, and Postdoctoral Mentor, he holds prestigious positions as the Dean of the College of Laboratory Animal Medicine and Director of the Laboratory Animal Center at the Liaoning University of Traditional Chinese Medicine in Shenyang, China. With a career dedicated to advancing the frontiers of cancer biology and pharmaceutical innovation, Prof. Zhao has established himself as a leading authority in tumor drug resistance mechanisms, molecular target discovery, molecular targeted drug development, and tumor immunotherapy research.Prof. Zhao’s academic journey reflects a blend of scientific rigor and innovative leadership. Prior to his current roles, he contributed significantly as Deputy Director of the Engineering Technology Center for TCM Innovation at Liaoning University of Traditional Chinese Medicine and as a Researcher at the Health Science Research Institute of China Medical University. His earlier tenure as an Associate Researcher at Shengjing Hospital, China Medical University, laid the groundwork for his expertise in translational medicine, fostering a seamless bridge between laboratory research and clinical applications.A prolific scholar, Prof. Zhao has authored and co-authored eighty-four academic papers, including thirty-one SCI-indexed publications with a cumulative impact factor of one hundred eighty-eight. Among these, five papers boast impact factors exceeding ten, with his highest-impact publication reaching an impressive twenty-seven point four. His scientific excellence is further reflected in the thirteen national patents he holds, with four as the first inventor, underscoring his role as a trailblazer in molecular oncology and therapeutic innovation.

Profile: Orcid

Featured Publications

Liu, Y., Guo, R., Xue, C., Zhang, X., Xiao, F., Zhao, X., Zhu, Z., & Li, K. (2025). Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition. Chemico-Biological Interactions.

Ke, W., Wang, H., Zhao, X., & Lu, Z. (2021). Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food & Function.

Sun, W., Ren, Y., Lu, Z., & Zhao, X. (2020). The potential roles of exosomes in pancreatic cancer initiation and metastasis. Molecular Cancer.

Ke, W., Zhao, X., & Lu, Z. (2020). Bcl-2 is essential for Foeniculum vulgare seed extract-induced apoptosis in lung cancer. Research Square.

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Reda Abdel-Hameed | Pharmaceutical Chemistry | Best Researcher Award

Prof. Dr. Reda Abdel-Hameed, University of Hail, Egypt

Prof. Dr. Reda Abdel-Hameed is a distinguished chemist specializing in applied physical chemistry. He earned his B.Sc. (1998), M.Sc. (2003), and Ph.D. (2006) from Al-Azhar University, Cairo. With over two decades in academia, he has served as a professor at Al-Azhar University and an associate professor at the University of Hail, Saudi Arabia. His prolific research includes 134 published papers on nanotechnology, drug design, and environmental chemistry. A leader in scientific innovation, he continues to shape the future of chemistry through groundbreaking studies and mentorship.

Publication Profile

Google Scholar

Education

Prof. Dr. Reda Abdel-Hameed 🎓 is a distinguished chemist with a strong academic background. He earned his B.Sc. in Chemistry in 1998 with an Excellent with Honor degree 🏅, followed by an M.Sc. in Applied Organic Chemistry in 2003 and a Ph.D. in Applied Physical Chemistry in 2006. His academic career began as a Demonstrator at Al-Azhar University (1998-2003) and progressed to Lecturer (2003-2006), Assistant Professor (2006-2012), and Associate Professor (2012-2017). He also served at Hail University, KSA (2009-2012). Since 2017, he has been a Full Professor at Al-Azhar University, contributing significantly to the field of chemistry 🔬.

Experience 

Prof. Dr. Reda Abdel-Hameed 📚 has an extensive teaching portfolio in chemistry across Al-Azhar University and Hail University. At Al-Azhar, he has taught courses in Physical Chemistry, Electrochemistry, Polymer Science, Industrial Chemistry, and more 🔬. At Hail University, he covered Applied Physical Chemistry, Quantum Chemistry, Medical Chemistry, and Petroleum Chemistry ⛽. Additionally, he played a key role in developing course specifications and descriptions. His contributions extend to authorship, with books like Introduction to Organic Chemistry, Applied Electrochemistry, and Nanocomposites as Corrosion Inhibitors 📖. His dedication to chemistry education continues to inspire students worldwide 🌍.

Awards

Prof. Dr. Reda Abdel-Hameed 🌍 is a globally recognized scientist, ranked among the world’s top 2% by Stanford University and Elsevier from 2019 to 2023 📊. His excellence in academia has earned him numerous accolades, including the Ideal Student Prize (1996-1997) 🏆, the Faculty of Science Award for Academic Affairs (2012), and the Excellence in Teaching Award (2017) 🎓. He was also honored for integrating technology into higher education (2010) and recognized as the Best Coordinator for Student Activities at Hail University (2016). A proud member of the Royal Society of Chemistry (RSC) 🔬, he continues to make remarkable contributions.

Research Focus

Prof. Dr. Reda S. Abdel-Hameed specializes in corrosion science and electrochemical applications ⚡🔬. His research focuses on developing corrosion inhibitors 🛡️ for metals, particularly in acidic and marine environments. He explores green chemistry approaches 🌱, including eco-friendly inhibitors derived from expired drugs 💊, polymers 🏗️, and heterocyclic compounds 🧪. His work advances electrochemical techniques for evaluating materials’ durability and protection in industrial applications 🏭. With significant contributions to nanotechnology-based inhibitors 🧬 and adsorption studies, his research benefits sectors like petrochemicals, metallurgy, and coatings 🏗️. His expertise in analytical electrochemistry helps mitigate corrosion-related challenges, ensuring sustainability and efficiency.

Publication Top Notes

Analytical application using modern electrochemical techniques

Ranitidine drugs as non-toxic corrosion inhibitors for mild steel in hydrochloric acid medium

Preparation of green cardanol-based epoxy and hardener as primer coatings for petroleum and gas steel in marine environment

Aminolysis of polyethylene terephthalate waste as corrosion inhibitor for carbon steel in HCl corrosive medium

Effect of expired drugs as corrosion inhibitors for carbon steel in 1M HCL solution

2-(2, 6-dichloranilino) phenyl acetic acid drugs as eco-friendly corrosion inhibitors for mild steel in 1M HCl

Expired Voltaren drugs as corrosion inhibitor for aluminium in hydrochloric acid

Nano-composite as corrosion inhibitors for steel alloys in different corrosive media

Corrosion inhibition and adsorption properties of some heterocyclic derivatives on C-steel surface in HCl